Effects of the enkephalin analog (d-Met2 Pro5)-enkephalinamide on α-melanocyte-stimulating hormone secretion

James A. Carr, Linda C. Saland, Ann Samora, Diana Tejeda

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


We used the met-enkephalin analog (d-Met2, Pro5)-enkephalinamide (DMPEA) to investigate enkephalinergic control of α-melanocyte-stimulating hormone (α-MSH) secretion. Systemic (s.c.) administration of DMPEA elevated plasma titers of α-MSH in a dose- and time-related manner. Pretreatment with the opiate antagonist naltrexone had no effect on basal plasma levels of α-MSH but blocked DMPEA-induced α-MSH release. Treatment with a dose of naltrexone sufficient to block DMPEA-induced secretion of α-MSH had no effect on stress-induced secretion of α-MSH. Although pretreatment with the dopamine receptor agonist apomorphine prevented DMPEA-induced α-MSH secretion, DMPEA had no effect on the synthetic activity of tuberohypophysial dopamine neurons as gauged by measuring the accumulation of 3,4-dihydroxyphenylalanine in the neurointermediate lobe (NIL) following administration of NSD-1015. In vitro treatment of isolated NILs with DMPEA resulted in a significant increase in α-MSH release. Naltrexone completely blocked the stimulatory effects of DMPEA on α-MSH release in vitro. Our results indicate that DMPEA stimulates α-MSH secretion by acting directly through opiate receptors at the level of the NIL.

Original languageEnglish
Pages (from-to)141-150
Number of pages10
JournalRegulatory Peptides
Issue number2
StatePublished - Sep 3 1993


  • Intermediate lobe
  • MSH
  • Naltrexone
  • Opiate
  • Pituitary
  • Stress


Dive into the research topics of 'Effects of the enkephalin analog (d-Met2 Pro5)-enkephalinamide on α-melanocyte-stimulating hormone secretion'. Together they form a unique fingerprint.

Cite this